Digital repository of Slovenian research organisations

Show document
A+ | A- | Help | SLO | ENG

Title:Tumor cell-based vaccine contributes to local tumor irradiation by eliciting a tumor model-dependent systemic immune response
Authors:ID Remic, Tinkara (Author)
ID Serša, Gregor (Author)
ID Levpušček, Kristina (Author)
ID Lampreht Tratar, Urša (Author)
ID Uršič Valentinuzzi, Katja (Author)
ID Cör, Andrej (Author)
ID Kamenšek, Urška (Author)
Files:URL URL - Source URL, visit https://www.frontiersin.org/articles/10.3389/fimmu.2022.974912/full
 
.pdf PDF - Presentation file, download (9,70 MB)
MD5: 80F557B3BB354B0E881DBA5E65758073
 
Language:English
Typology:1.01 - Original Scientific Article
Organization:Logo OI - Institute of Oncology
Abstract:Multimodal treatment approaches, such as radio-immunotherapy, necessitate regimen optimization and the investigation of the interactions of different modalities. The aim of this study was two-fold. Firstly, to select the most effective combination of irradiation and the previously developed tumor cell-based vaccine and then to provide insight into the immune response to the selected combinatorial treatment. The study was performed in immunologically different murine tumor models: B16F10 melanoma and CT26 colorectal carcinoma. The most effective combinatorial treatment was selected by comparing three different IR regimens and three different vaccination regimens. We determined the local immune response by investigating immune cell infiltration at the vaccination site and in tumors. Lastly, we determined the systemic immune response by investigating the amount of tumor-specific effector lymphocytes in draining lymph nodes. The selected most effective combinatorial treatment was 5× 5 Gy in combination with concomitant single-dose vaccination (B16F10) or with concomitant multi-dose vaccination (CT26). The combinatorial treatment successfully elicited a local immune response at the vaccination site and in tumors in both tumor models. It also resulted in the highest amount of tumor-specific effector lymphocytes in draining lymph nodes in the B16F10, but not in the CT26 tumor-bearing mice. However, the amount of tumor-specific effector lymphocytes was intrinsically higher in the CT26 than in the B16F10 tumor model. Upon the selection of the most effective combinatorial treatment, we demonstrated that the vaccine elicits an immune response and contributes to the antitumor efficacy of tumor irradiation. However, this interaction is multi-faceted and appears to be dependent on the tumor immunogenicity.
Keywords:experimental oncology, multimodal treatment, radio-imunotherapy
Publication status:Published
Publication version:Version of Record
Publication date:05.09.2022
Publisher:MDPI AG
Year of publishing:2022
Number of pages:str. 1-12
Numbering:Vol. 13
PID:20.500.12556/DiRROS-15470 New window
UDC:602.6/.7
ISSN on article:1664-3224
DOI:10.3389/fimmu.2022.974912 New window
COBISS.SI-ID:120231939 New window
Copyright:by Authors
Note:Nasl. z nasl. zaslona; Opis vira z dne 5. 9. 2022;
Publication date in DiRROS:14.09.2022
Views:942
Downloads:527
Metadata:XML DC-XML DC-RDF
:
Copy citation
  
Share:Bookmark and Share


Hover the mouse pointer over a document title to show the abstract or click on the title to get all document metadata.

Record is a part of a journal

Title:Frontiers in immunology
Shortened title:Front. immunol.
Publisher:Frontiers Research Foundation
ISSN:1664-3224
COBISS.SI-ID:30774233 New window

Document is financed by a project

Funder:ARRS - Slovenian Research Agency
Project number:P3-0003-2022
Name:Razvoj in ovrednotenje novih terapij za zdravljenje malignih tumorjev

Licences

License:CC BY 4.0, Creative Commons Attribution 4.0 International
Link:http://creativecommons.org/licenses/by/4.0/
Description:This is the standard Creative Commons license that gives others maximum freedom to do what they want with the work as long as they credit the author.
Licensing start date:14.09.2022

Secondary language

Language:Slovenian
Keywords:eksperimentalna onkologija, multimodalno zdravljenje, radio-imunoterapija


Back